sign in sign up
<<
Home , Charles Kelman, Eye surgery

Speeding the development of new and diagnostics for patients New Horizons Forum

Friday, February 9, 2018 Palace Hotel, San Francisco, CA

© Aerie Pharmaceuticals, Inc. Irvine, CA 92614 Follow the meeting on Twitter: #Glaucoma360 MLR-0002 Glaucoma Research Foundation thanks the following sponsors WELCOME for their generous support of Glaucoma 360

PLATINUM It is our sincere pleasure to welcome you to the 7th Annual Glaucoma 360: New Horizons Forum, hosted by Glaucoma Research Foundation.

This important meeting provides a unique opportunity to bring together leaders in , science, industry, venture capital, and the FDA to discuss emerging ideas in glaucoma and encourage collaboration to accelerate their development for clinical use.

Since its establishment in 2012, this annual forum continues to grow and provide the ultimate opportunity to highlight important advances and facilitate networking between these essential groups. As a result, there are now more effective therapies and diagnostic tools in clinical practice today to help doctors manage the disease more effectively.

But, unmet medical needs remain in glaucoma. Glaucoma Research Foundation is resolute in its mission to preserve vision and continue its role as a catalyst in the advancement of research towards new treatments and a cure.

SILVER Glaucoma 360 would not be possible without the generous and selfless contributions of so many including: members of our Advisory Board, Program and Steering Committees who have volunteered their time to build an outstanding agenda; our dedicated sponsors who have helped to underwrite this event; our speakers, presenters, and panelists who are ready to share their expertise and unique perspectives; our attendees; the support of our Board of Directors and staff at Glaucoma Research Foundation; and the hard working team at The Palace Hotel. Over the past seven years, the field has grown substantially and we are honored and grateful to all of you, for your ongoing dedication to helping patients. Because of your commitment, we now have more options to care for patients than ever before.

All proceeds from Glaucoma 360 events will support Glaucoma Research Foundation’s sight-saving endeavors such as the Catalyst for a Cure, a unique collaborative approach to uncover new diagnostic and treatment options for glaucoma. Thank you for your wonderful partnership in our mission. Together, we can truly make a difference in the lives of people living with glaucoma. BRONZE

Akorn, Inc. IRIDEX Corporation Optos, Inc. Beaver-Visitec International Lumenis Vision Optovue, Inc. Adrienne L. Graves, PhD Andrew G. Iwach, MD Co-Founder and Co-Chair, Glaucoma 360 Co-Founder and Co-Chair, Glaucoma 360 Ellex Mobius Therapeutics, LLC Quantel Medical Director, Glaucoma Research Foundation Board Chair, Glaucoma Research Foundation Haag-Streit USA Nidek Inc. Shire Icare USA, Inc. Ophthalmic Mutual Insurance Sight Sciences, Inc. Company

Wi-Fi sponsored by Santen Inc., Network: Palace Meetings, Password: 2018G360 2018 New Horizons Forum 1 PROGRAM Follow the meeting on Twitter: #Glaucoma360

7:30 – 8:00 am REGISTRATION, BREAKFAST AND EXHIBITS Panelists • Allergan, Inc., Jag Dosanjh, Senior Vice President, Care • Glaukos Corporation, Chris M. Calcaterra, Chief Operating Officer • Heidelberg Engineering, Kfir Azoulay, MBA, Head of Strategy 8:00 – 8:06 am WELCOME AND OPENING REMARKS • Johnson & Johnson Vision, Jane Rady, Vice President, Business Development, Surgical Adrienne L. Graves, PhD and Andrew G. Iwach, MD • New World Medical, Rafael Chan, Chief Commercial Officer Co-Founders and Co-Chairs, Glaucoma 360 • Santen Inc., Ram Palanki, PharmD, Senior Vice President of Commercial, Americas • Carl Zeiss Meditec, Inc., Angelo Rago, Global Head, Ophthalmic Diagnostics 8:06 – 8:32 am OPENING KEYNOTE ADDRESS — Drs. Henry and Frederick Sutro Memorial Lecture Interventional Glaucoma: The Why, The Who, and The How 10: 11:26 – 11:31 am INDUSTRY SPOTLIGHT — Allergan, Inc. Speaker Iqbal Ike K. Ahmed, MD, FRCSC Speaker Jag Dosanjh Medical Director, Prism Eye Institute; Associate Professor of , University of Toronto; Senior Vice President, Eye Care Clinical Professor of Ophthalmology, University of Utah 11:31 – 12:09 pm FUNDING INNOVATIONS: VENTURE CAPITAL PANEL DISCUSSION MORNING CATALYST Moderators Emmett Cunningham, Jr., MD, PhD, MPH Joel S. Schuman, MD, FACS Partner, Clarus Ventures Professor and Chairman of Ophthalmology, NYU Langone Medical Center, NYU School of Medicine; Andrew Gitkin Professor of Electrical and Computer Engineering, NYU Tandon School of Engineering Managing Director and Head of West Coast Biotechnology Banking, Piper Jaffray Panelists • Juliet Bakker, Managing Director and Founder, Longitude Capital • William J. Link, PhD, Founder, Flying L Partners, Managing Director, Versant Ventures 8:34 – 9:09 am NEW HORIZONS IN VIRTUAL REALITY • Heather Preston, MD, Partner and Managing Director, TPG Biotech Moderators Andrew D. Huberman, PhD • Christy Shaffer, PhD, Partner, Hatteras Venture Partners Associate Professor of Neurobiology and Ophthalmology, Stanford University; Member, Catalyst for a Cure Biomarker Initiative Felipe Medeiros, MD, PhD Professor of Ophthalmology, Vice Chair, Technology, Duke University School of Medicine 10: 12:09 – 12:14 pm INDUSTRY SPOTLIGHT — Aerie Pharmaceuticals, Inc. Presenting • nGoggle, Inc., Felipe Medeiros, MD, PhD, Professor of Ophthalmology, Vice Chair, Technology, Duke University School of Medicine Speaker Thomas A. Mitro Companies • Vivid Vision, Ben Backus, PhD, Chief Science Officer President and Chief Operating Officer

9:09 – 9:14 am INDUSTRY SPOTLIGHT — Santen Inc. Speaker Ram Palanki, PharmD 12:14 – 1:10 pm NETWORKING BUFFET LUNCHEON Senior Vice President of Commercial, Americas

9:14 – 10:21 am NEW HORIZONS IN GLAUCOMA DEVICES AFTERNOON CATALYST Moderators E. Randy Craven, MD George A. Cioffi, MD Chief, Wilmer Eye Institute – Bethesda; Associate Professor of Ophthalmology, Johns Hopkins University School of Medicine Edward S. Harkness Professor and Chairman, Columbia University College of and Surgeons; Eydie G. Miller-Ellis, MD Ophthalmologist-in-Chief, New York-Presbyterian /Columbia University Medical Center Professor of Clinical Ophthalmology, Scheie Eye Institute, University of Pennsylvania Presenting • Alcon, a Novartis Division, Richard A. Lewis, MD, Co-Founder, Sacramento Eye Consultants 1:12 – 2:30 pm NEW HORIZONS IN GLAUCOMA DRUG DELIVERY Companies • Allergan, Inc., Michael Robinson, MD, Vice President and Therapeutic Area Head, Anterior Segment and Consumer Eye Care Moderators James D. Brandt, MD • Camras Vision, Ray Krauss, Chief Executive Officer Director of Glaucoma Service, Professor of Ophthalmology and Visual Science, UC Davis • Ivantis, Inc., Brett A. Trauthen, Chief Scientific Officer Anne L. Coleman, MD, PhD • LumiThera, Clark Tedford, PhD, President and Chief Executive Officer Vice Chair of Department of Ophthalmology, Stein Eye Institute, Frances and Ray Stark Foundation Professor of Ophthalmology, • MicroOptx, Chris Pulling, Chief Executive Officer Stein Eye Institute of the David Geffen School of Medicine, University of California, Los Angeles, Professor of Epidemiology, • Santen Inc., Leonard Pinchuk, PhD, DSc (h.c.), NAE, Founder and Chief Scientific Officer, InnFocus, Inc., a Santen company Jonathan and Karin Fielding School of , University of California, Los Angeles • Sight Sciences, Inc., Steven Vold, MD, Founder and Chief Executive Officer, Vold Vision; Chief Medical Editor,Glaucoma Today Presenting • Eyenovia, Inc., Shan Lin, MD, Professor of Clinical Ophthalmology, Director, Glaucoma Service, and Director Glaucoma Companies Fellowship Program, Department of Ophthalmology, UCSF • Glaukos Corporation, Jeff Wells, PharmD, Senior Vice President, Clinical, Regulatory and Quality 10:21 – 10:51 am BREAK, EXHIBITS AND NETWORKING OPPORTUNITY • Graybug Vision, Inc., Jeffrey L. Cleland, PhD, President and Chief Executive Officer • Mati Therapeutics, Christopher A. Muller, Chief Commercial Officer • Ocular Therapeutix, Michael H. Goldstein, MD, MBA, Chief Medical Officer • Otero Therapeutics, Morgan V. Fedorchak, PhD, President and Chief Technology Officer; Assistant Professor of Ophthalmology, 10:51 – 11:26 am INDUSTRY PANEL DISCUSSION: GLAUCOMA DEVICES Bioengineering and Clinical & Translational Sciences, University of Pittsburgh Moderators Malik Kahook, MD • Retroject, Inc., Molly Walsh, MD, Founder and Chief Executive Officer Slater Family Endowed Chair of Ophthalmology, Vice Chair, Clinical and Translational Research; • UCSF, Tejal Desai, PhD, Professor and Chair, Department of Bioengineering and Chief, Glaucoma Service and Director, Glaucoma Fellowship, Professor of Ophthalmology, University of Colorado Therapeutic Sciences, School of , UCSF Steven Vold, MD • USC, Mark S. Humayun, MD, PhD, Cornelius J. Pings Chair in Biomedical Sciences, Founder and Chief Executive Officer, Vold Vision; Chief Medical Editor,Glaucoma Today Professor of Ophthalmology, and Integrative Anatomical Sciences, Director of the Institute for Biomedical Therapeutics and Co-Director of the USC Roski Eye Institute

2 Glaucoma Research Foundation 2018 New Horizons Forum 3 PROGRAM (continued) LEADERSHIP

2:30 – 2:35 pm INDUSTRY SPOTLIGHT — Novartis Alcon Pharmaceuticals Speaker Melissa Liew, MD Vice President and US Medical Head of Ophthalmology THOMAS M. BRUNNER filtering , application of optical coherence tomography in glaucoma, President and Chief Executive Officer, selective laser , and numerous drug trials. He currently serves as 2:35 – 3:20 pm NEW HORIZONS IN PHARMACEUTICALS Steering Committee, Glaucoma 360 a scientific reviewer for many top professional publications. Recently he received Moderators Lama Al-Aswad, MD, MPH Glaucoma Research Foundation the Academy’s Life Achievement Award and the Academy’s Secretariat Award. Associate Professor of Ophthalmology and Glaucoma Fellowship Director, Columbia University Medical Center Mr. Brunner joined the Glaucoma Research Robert D. Fechtner, MD Foundation after a 30-year career in the Professor and Chair of Ophthalmology, Upstate Medical University, SUNY; Director, Glaucoma Division at Rutgers New Jersey ophthalmic laser business. He helped introduce major advances including laser photocoagulation L. JAY KATZ, MD Presenting • Aerie Pharmaceuticals, Inc., Thomas A. Mitro, President and Chief Operating Officer for and laser treatment for secondary and Director, Glaucoma Service, Companies • Allysta Pharmaceuticals, Henry Hsu, MD, Chief Executive Officer glaucoma. He served 25 years on the Board of Directors for the American Society Wills Eye Hospital • Bausch + Lomb, Robert Kissling, MD, Vice President, Medical Affairs for Laser Medicine and Surgery who granted him a “Lifetime Achievement” Professor of Ophthalmology, • Glauconix Therapeutics, Karen Y. Torrejon, PhD, Founder and Chief Science Officer Jefferson Medical College • Novartis Alcon Pharmaceuticals, Melissa Liew, MD, Vice President and US Medical Head of Ophthalmology award. As an advisor or board member for startup companies, he supports new Steering Committee, Glaucoma 360 product development to treat glaucoma and other eye diseases. Tom graduated Glaucoma Research Foundation from Lehigh University with a degree in electrical engineering and a MBA from In 2017 Dr. Katz was appointed the Chief 3:20 – 3:50 pm BREAK, EXHIBITS AND NETWORKING OPPORTUNITY the University of Delaware. Medical Officer of Glaukos Corporation. He is on the advisory boards of Bausch + Lomb, Allergan, Aerie, and Merck. Dr. Katz is a former member of the board and past treasurer of the American Glaucoma 3:50 – 4:25 pm INDUSTRY PANEL DISCUSSION: PHARMACEUTICALS ADRIENNE L. GRAVES, PHD Society and a diplomate and associate examiner for the American Board of Moderators Alan Crandall, MD Ophthalmology. His interests in glaucoma include drug evaluation, laser and Presidential Professor of Ophthalmology and Visual Sciences, Senior Vice Chair, Director of Glaucoma and ; Independent Director, medical management, scanning methodologies, and glaucoma Co-Director, Division of International Ophthalmology, John A. Moran Eye Center, Global Outreach Division, University of Utah Akorn, Inc., Nicox S.A., Surface surgical techniques. After attending Yale University School of Medicine, he James C. Tsai, MD, MBA, FACS Pharmaceuticals, and TearLab Corporation Chair of Ophthalmology, Mount Sinai Health System, President, New York Eye and Ear Infirmary Co-Founder and Co-Chair, Glaucoma 360 completed his ophthalmology at Yale and received glaucoma training Panelists • Bausch + Lomb, Tracy M. Valorie, MBA, Senior Vice President and General Manager, US Pharmaceutical and Surgical Board of Directors, at Wills Eye Hospital. • Novartis Alcon Pharmaceuticals, Melissa Liew, MD, Vice President and US Medical Head of Ophthalmology Glaucoma Research Foundation • Omar Consulting, Cheryl Rowe-Rendleman, PhD, Managing Consultant Adrienne L. Graves, PhD is a visual scientist • Santen Inc., Ram Palanki, PharmD, Senior Vice President of Commercial, Americas by training and a global industry leader in ophthalmology. From 2002 to 2010 Dr. Graves was President and Chief RUTH D. WILLIAMS, MD 4:25 – 4:30 pm INDUSTRY SPOTLIGHT — Bausch + Lomb Executive Officer of the US arm of Santen Inc., Japan’s largest ophthalmic President, Speaker Tracy M. Valorie, MBA pharmaceutical company. Dr. Graves held various Research and Development Senior Vice President and General Manager, US Pharmaceutical and Surgical Wheaton Eye roles with Alcon Laboratories including Director of International Ophthalmology. Vice Chair, Board of Directors, In 2015, the Glaucoma Research Foundation gave her the Catalyst Award for Steering Committee, Glaucoma 360 4:30 – 5:08 pm FDA: GETTING TO NEW HORIZONS her dedication and leadership in advancing ophthalmic innovation. Dr. Graves Glaucoma Research Foundation Moderators Reay H. Brown, MD received her PhD from the University of Michigan and did a postdoctoral Atlanta Ophthalmology Associates Dr. Williams is the President of the Wheaton Eye Cynthia Mattox, MD, FACS fellowship in visual neuroscience at the University of Paris. Clinic, a 74-year-old ophthalmology practice Director of the Glaucoma and Cataract Service, New England Eye Center, Associate Professor and Vice-Chair, providing eye care to more than 140,000 Department of Ophthalmology, School of Medicine patients annually. She is a past president of the American Academy of Panelists • Wiley A. Chambers, MD, Deputy Director, Division of Transplant & Ophthalmology Products, Center for Drug Evaluation & Ophthalmology and represented ophthalmology at the AMA for a decade and Research, FDA ANDREW G. IWACH, MD chaired its specialty section. Dr. Williams received a Senior Achievement Award • Eugene de Juan, Jr., MD, Founder and Vice-Chairman, ForSight Labs Executive Director, from the Academy and was chosen by her peers for the prestigious “Top Doctors” • Malvina Eydelman, MD, Director, Division of Ophthalmic and Ear, Nose and Throat Devices, FDA Glaucoma Center of San Francisco and Award in Chicago. After attending Rush Medical College, she completed an • Kuldev Singh, MD, MPH, Professor of Ophthalmology, Director, Glaucoma Service, Stanford University School of Medicine Executive Director, ophthalmology residency at California Pacific Medical Center in San Francisco Glaucoma Research and Education Group and a glaucoma fellowship at Shaffer Associates and the University of California Co-Founder and Co-Chair, Glaucoma 360 5:08 – 5:21 pm FORUM SUMMATION San Francisco. Speaker Richard A. Lewis, MD Chair, Board of Directors, Co-Founder, Sacramento Eye Consultants Glaucoma Research Foundation Since 2000 Dr. Iwach has served on the Board 5:21 – 5:30 pm CLOSING REMARKS of Directors for the Glaucoma Research Foundation. He is a Co-Founder of Adrienne L. Graves, PhD and Andrew G. Iwach, MD the Eye Surgery Center of San Francisco and is an Associate Clinical Professor of Ophthalmology at UCSF and is on the clinical faculty at California Pacific Medical Center. Dr. Iwach’s clinical research focuses on mitomycin-C use in 5:30 – 7:00 pm RECEPTION, EXHIBITS, AND NETWORKING OPPORTUNITY

4 Glaucoma Research Foundation 2018 New Horizons Forum 5 ADVISORY BOARD

STUART B. ABELSON, MBA EUGENE DE JUAN, JR., MD RICHARD L. LINDSTROM, MD KULDEV SINGH, MD, MPH President, Chief Executive Officer Founder and Vice-Chairman Founder Professor of Ophthalmology Ora, Inc. ForSight Labs Minnesota Eye Consultants, PA Director, Glaucoma Service Stanford University School of Medicine

ANTHONY P. ADAMIS, MD JOHN G. FLANAGAN, PHD, FCOPTOM WILLIAM J. LINK, PHD GEORGE SPAETH, MD Vice President, Global Head of Ophthalmology Dean, School of and Professor of Optometry Founder Louis Esposito Research Professor of Ophthalmology Genentech, Inc. and Vision Science Flying L Partners Director Emeritus, Glaucoma Service University of California, Berkeley Managing Director Wills Eye Hospital/Jefferson Medical College Versant Ventures

JAMES D. BRANDT, MD DAVID GUYER, MD CYNTHIA MATTOX, MD, FACS ELLEN STRAHLMAN, MD, MHSC Director of Glaucoma Service Partner Director of the Glaucoma and Cataract Service, Chief Medical Officer and Senior Vice President, Professor of Ophthalmology and Vision Science SV Life Sciences Advisers, LLC New England Eye Center Research & Development University of California, Davis Associate Professor and Vice-Chair, Becton, Dickinson and Company Department of Ophthalmology Tufts University School of Medicine

ERNEST CAVIN, PHD EVE HIGGINBOTHAM, SM, MD JAMES MAZZO TRACY M. VALORIE, MBA President Vice Dean, Inclusion and Diversity Global President Ophthalmic Devices Senior Vice President and General Manager, Haag-Streit USA Perelman School of Medicine Carl Zeiss Meditec, Inc. US Pharmaceutical and Surgical University of Pennsylvania Bausch + Lomb

PAUL CHANEY H. DUNBAR HOSKINS, JR., MD J. CASEY MCGLYNN, JD ROBERT N. WEINREB, MD President and Chief Executive Officer Co-Founder and Emeritus Director Partner Chairman & Director, Shiley Eye Center PanOptica, Inc. Glaucoma Research Foundation Wilson Sonsini Goodrich & Rosati Director, Hamilton Glaucoma Center Former Executive Vice President University of California, San Diego American Academy of Ophthalmology

GEORGE A. CIOFFI, MD WENDE HUTTON GARY D. NOVACK, PHD RUTH D. WILLIAMS, MD Jean and Richard Deems Professor of Ophthalmology General Partner President President Edward S. Harkness Professor and Chairman Canaan Partners PharmaLogic Development, Inc. Wheaton Eye Clinic Columbia University College of Physicians and Surgeons

ALAN S. CRANDALL, MD ELIOT LAZAR, MD DAVID E.I. PYOTT, CBE M. ROY WILSON, MD, MS Presidential Professor of Ophthalmology President Former Chairman of the Board, President and Visual Services elCON Medical President and Chief Executive Officer (1998-2015) Wayne State University Senior Vice Chair, Director of Glaucoma and Cataract Allergan, Inc. Co-Director, Division of International Ophthalmology John A. Moran Eye Center

EMMETT CUNNINGHAM, JR., MD, PAUL P. LEE, MD, JD THOMAS W. SAMUELSON, MD PHD, MPH F. Bruce Fralick Professor and Chair, Founding Partner, Minnesota Eye Consultants Managing Partner Department of Ophthalmology and Visual Sciences Adjunct Associate Professor of Ophthalmology, Clarus Ventures Director, W.K. Kellogg Eye Center University of Minnesota University of Michigan

6 Glaucoma Research Foundation 2018 New Horizons Forum 7 PROGRAM COMMITTEE FOR THE REDUCTION OF IOP IN MILD TO MODERATE PRIMARY OPENANGLE GLAUCOMA AT THE TIME OF

IQBAL IKE F. AHMED, MD, FRCSC EYDIE G. MILLER-ELLIS, MD Medical Director, Prism Eye Institute Professor of Clinical Ophthalmology Associate Professor of Ophthalmology, University of Toronto Director, Glaucoma Service, Scheie Eye Institute Clinical Professor of Ophthalmology, University of Utah University of Pennsylvania

LAMA A. AL-ASWAD, MD MILDRED M.G. OLIVIER, MD Associate Professor of Ophthalmology Professor and Assistant Dean for Diversity and Learning Environment Columbia University Medical Center Rosalind Franklin University of Medicine and Science Chicago Medical School Associate Clinical Professor, Midwestern University CEO and Founder, Midwest Glaucoma Center, P.C.

JOEL S. SCHUMAN, MD, FACS ONE CYPASS® MICROSTENT IS ALL IT TAKES TO CONNECT ANNE L. COLEMAN, MD, PHD and done Vice Chair of Department of Ophthalmology, Stein Eye Institute, Professor and Chairman of Ophthalmology TO SAFE, CONSISTENT, LONGTERM IOP CONTROL Frances and Ray Stark Foundation Professor of Ophthalmology, Stein NYU Langone Medical Center, Eye Institute of the David Geffen School of Medicine, University of New York University School of Medicine California, Los Angeles, Professor of Epidemiology, Jonathan and Karin Professor of Electrical and Computer Engineering Fielding School of Public Health, University of California, Los Angeles NYU Tandon School of Engineering 1,2 IN THE COMPASS STUDY AT TWO YEARS : ROBERT D. FECHTNER, MD ROBERT STAMPER, MD • 72.5% of patients achieved a ≥20% reduction in IOP (n=374) Empire Innovation Scholar and Chair Distinguished Professor of Clinical Ophthalmology Department of Ophthalmology Director Emeritus, Glaucoma Service • 93% of patients were medication free* Upstate Medical University University of California, San Francisco Executive Vice President, World Glaucoma Association • Safety profi le similar to cataract surgery alone

LARRY HAIMOVITCH JAMES C. TSAI, MD, MBA, FACS FOR AN EXPERIENCE LIKE NO OTHER, CONNECT WITH AN ALCON REPRESENTATIVE TODAY. Founder Chair of Ophthalmology, Mount Sinai Health System Haimovitch Medical Technology Consultants President, New York Eye & Ear Infirmary *Those patients who attained an unmedicated mean diurnal IOP reduction of 20% or more as compared to baseline in the absence of IOP-a™ ecting surgery during the study. References: 1. CyPass® Micro-Stent Instructions for Use. 2. Vold S, Ahmed IIK, Craven ER, et al. Two-year COMPASS trial results: supraciliary microstenting with phacoemulsifi cation in patients with open-angle glaucoma and cataracts. Ophthalmology. 2016;123(10):2103-2112. L. JAY KATZ, MD © 2017 Novartis 09/17 US-CYP-17-E-2272 DEVESH K. VARMA, BENG, MD, FRSC Director, Glaucoma Service Assistant Professor, Faculty of Medicine University of Toronto IMPORTANT PRODUCT INFORMATION Wills Eye Institute CAUTION: FEDERAL €USA‚ LAW RESTRICTS THIS DEVICE TO SALE BY OR ON THE ORDER OF A . INDICATION: The Micro-Stent is Professor of Ophthalmology indicated for use in conjunction with cataract surgery for the reduction of (IOP) in adult patients with mild to moderate primary open-angle Thomas Jefferson University glaucoma (POAG). CONTRAINDICATIONS: Use of the CyPass Micro-Stent is contraindicated in the following circumstances or conditions: (1) in with angle- closure glaucoma; and (2) in eyes with traumatic, malignant, uveitic, or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle. MRI INFORMATION: The CyPass Micro-Stent is magnetic resonance (MR) Safe: the implant is constructed of polyimide material, a non-conducting, non-metallic, non- RICHARD A. LEWIS, MD STEVEN VOLD, MD magnetic polymer that poses no known hazards in all magnetic resonance imaging environments. WARNINGS: should be performed prior to surgery to exclude peripheral anterior synechiae (PAS), rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper Co-Founder Founder and CEO placement of the stent and pose a hazard. PRECAUTIONS: The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. Sacramento Eye Consultants Vold Vision The safety and effectiveness of the CyPass Micro-Stent has not been established as an alternative to the primary treatment of glaucoma with medications, in patients 21 years or younger, in eyes with signi cant prior trauma, chronic in ammation, eyes with an abnormal anterior segment, eyes with chronic in ammation, eyes with glaucoma Past President, American Glaucoma Society Chief Medical Editor associated with vascular disorders, pseudophakic eyes with glaucoma, eyes with uveitic glaucoma, eyes with pseudoexfoliative or pigmentary glaucoma, eyes with other Past President, American Society of Cataract and Refractive Glaucoma Today secondary open-angle , eyes that have undergone prior incisional or cilioablative procedures, eyes with laser trabeculoplasty performed ≤ 3 Surgery months prior to the surgical screening visit, eyes with unmedicated IOP less than 21 mmHg or greater than 33 mmHg, eyes with medicated IOP greater than 25 mmHg, in the setting of complicated cataract surgery with iatrogenic injury to the anterior or posterior segment, and when implantation is without concomitant cataract surgery with IOL SHAN LIN, MD BARBARA WIROSTKO, MD implantation for visually signi cant cataract. The safety and effectiveness of use of more than a single CyPass Micro-Stent has not been established. ADVERSE EVENTS: In a randomized, multicenter clinical trial comparing cataract surgery with the CyPass Micro-Stent to cataract surgery alone, the most common postoperative adverse events Professor of Clinical Ophthalmology Clinical Adjunct Associate Professor included: BCVA loss of 10 or more letters at 3 months after surgery (8.8% for the CyPass Micro-Stent vs. 15.3% for cataract surgery only); anterior chamber cell and  are Director, Glaucoma Service, and Director, University of Utah School of Medicine requiring steroid treatment 30 or more days after surgery (8.6% vs. 3.8%); worsening of visual eld mean deviation by 2.5 or more decibels (6.7% vs. 9.9%); IOP increase of 10 or more mmHg 30 or more days after surgery (4.3% vs. 2.3%); and corneal edema 30 or more days after surgery, or severe in nature (3.5% vs. 1.5%). ATTENTION: Glaucoma Fellowship Program PLEASE REFER TO THE INSTRUCTIONS FOR A COMPLETE LIST OF CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, Department of Ophthalmology AND ADVERSE EVENTS. University of California, San Francisco

2018 New Horizons Forum 9 100438 US-CYP-17-E-2272 G360.indd 1 1/4/18 12:59 PM SPEAKERS, MODERATORS, PARTICIPANTS

Opening Keynote Address DRS. HENRY AND FREDERICK SUTRO MEMORIAL LECTURER

IQBAL IKE F. AHMED, MD, FRCSC Medical Director, Prism Eye Institute Associate Professor of Ophthalmology, University of Toronto Clinical Professor of Ophthalmology, University of Utah INTERVENTIONAL GLAUCOMA: THE WHY, THE WHO, AND THE HOW Dr. Ahmed’s areas of expertise include: surgical management of glaucoma, the complex cataract, and management of cataract and intraocular complications. He is actively involved in research and at a national and international level and has received many research grants and has designed diamond scalpels for glaucoma surgery, microsurgical instrumentation, and devices, implants, and techniques for the management of the dislocated cataract and glaucoma. He has published numerous peer-reviewed articles and book chapters and has won many awards and honors for papers, posters, and videos and has given more than 500 scientific presentations and lectures around the world.

LAMA AL-ASWAD, MD, MPH BEN BACKUS, PHD Associate Professor of Ophthalmology Vivid Vision Columbia University Medical Center Chief Science Officer Dr. Al-Aswad is an Associate Professor of Ben Backus was a professor at SUNY Optometry Ophthalmology at CUMC and the glaucoma in New York until his recent move to be CSO at fellowship director. She received her MD from Vivid Vision in San Francisco. Dr. Backus is now Damascus University, and completed a research applying his knowledge of psychophysics to fellowship at the MEEI, Harvard Medical School. develop a new mobile light-weight perimeter She completed her residency at SUNY Downstate and Fellowship at UT Memphis. for people with glaucoma to do visual field testing at home. He trained in She received her MPH from Columbia University, Mailman School of Public mathematics (BA Swarthmore), human vision (PhD UC Berkeley), and visual Health with an emphasis on healthcare policy and management. She has been neuroscience (postdoc Stanford). The NIH, NSF, and HFSP fund his research. the director of the glaucoma screening program since 2006 and in 2016 she launched Tele-ophthalmology for the four leading causes of blindness.

KFIR AZOULAY, MBA JULIET BAKKER Corporate Head of Strategy Managing Director and Founder Heidelberg Engineering, Inc. Longitude Capital At Heidelberg Engineering, Mr. Azoulay oversees Prior to Longitude Capital, Ms. Bakker was a business development as well as the company’s Managing Director of Pequot Ventures where other strategic initiatives. Prior to Heidelberg she founded the life sciences investment practice. Engineering Mr. Azoulay served for several Prior to Pequot, she was Director, Strategic years as VP & General Manager of Lumenis’ Planning and Director, Operations of Waste global ophthalmology business. Mr. Azoulay currently also serves on the Board Management International. Previously, she was a sell-side equity analyst with of Directors of Gauss Infomed (China) and Medisoft Ltd. (UK) — two leading Banque Paribas. Ms. Bakker began her career as an investment banker in the companies in ophthalmic healthcare IT solutions. Mr. Azoulay holds an MBA corporate finance department at PaineWebber. Ms. Bakker holds an M.P.A. from from the Massachusetts Institute of Technology (MIT) and he also completed the the John F. Kennedy School of Government at Harvard University and a BSc from ophthalmology science program (BCSC) at Columbia University. the College of Agriculture and Life Sciences at Cornell University (“CALS”).

2018 New Horizons Forum 11 B:8.75” T:8.5” S:7.5” SPEAKERS, MODERATORS, PARTICIPANTS

JAMES D. BRANDT, MD WILEY A. CHAMBERS, MD Professor of Ophthalmology and Vision Science Deputy Director, Division of Transplant and Director of Glaucoma Service Ophthalmology Products Center for Drug University of California, Davis Evaluation and Research FDA Dr. Brandt received his BS from Yale University and an MD from Harvard Medical School, then In addition to his position at the FDA, pursued a two-year post-doctoral research Dr. Chambers is a Clinical Professor of fellowship at the Schepens Eye Research Ophthalmology and Adjunct Assistant Professor Institute before his residency at the Doheny Eye Institute. His research interests of Computer Medicine at The George Washington University. He joined the FDA are in the material properties of the eye as they affect the measurement of in 1987 and in 1990 became a Supervisory Medical Officer for Ophthalmologic intraocular pressure and the physiology of outflow resistance. He is currently Drug Products. He has supervisory responsibility for the clinical review of collaborating with researchers in the fields of nanotechnology, micro-fabrication ophthalmologic drug products and ophthalmic therapeutic biologic products and biomedical engineering to develop new methods to measure outflow submitted to the FDA for study and potential approval. Dr. Chambers received resistance in the living . numerous Public Health Service, FDA and Center for Drug Evaluation and INTRODUCING VYZULTA Research awards for his work. REAY H. BROWN, MD RAFAEL CHAN Now available in nationwide. Glaucoma Editor of EyeWorld Chief Commercial Officer Atlanta Ophthalmology Associates New World Medical

B:11.25” Dr. Brown did his training at Harvard College, Mr. Chan recently joined New World Medical as S:10” T:11” University of Michigan Medical School, the Chief Commercial Officer. Prior to joining New Wilmer Eye Institute at Johns Hopkins and the World Medical, Mr. Chan spent over 16 years Bascom Palmer Eye Institute. He was the Pamela with Alcon in a variety of commercial strategy Firman professor at Emory University before and leadership positions across Surgical and founding Atlanta Ophthalmology Associates. Their patents on trabecular bypass Pharmaceutical franchises, most recently as Head of Marketing for US Surgical. are fundamental to MIGS technology and cover aspects of many innovative Mr. Chan holds a Bachelor’s Degree and MBA from Vanderbilt University. devices including the iStent (Glaukos) and the Hydrus (Ivantis). Dr. Brown has received the Innovator Award from the American Glaucoma Society and the 2017 Charles Kelman Innovator Award from the American Society of Cataract and .

CHRIS M. CALCATERRA GEORGE A. CIOFFI, MD Chief Commercial Officer Edward S. Harkness Professor and Chairman For more information, Glaukos Corporation Columbia University College of Physicians and Surgeons Mr. Calcaterra has served as Chief Commercial visit vyzultanow.com Ophthalmologist-in-Chief Officer since April 2008. Prior to joining Glaukos, New York Presbyterian Hospital/Columbia he was Senior VP at Advanced Medical Optics, University Medical Center Inc. and was responsible for its cataract business. Dr. Cioffi is the Edward S. Harkness Professor and Prior to that, Mr. Calcaterra held VP positions Chairman at Columbia University, Department in sales and marketing roles at Advanced Medical Optics, Inc., as well as its of Ophthalmology. He also holds the Jean and Richard Deems Endowed predecessor surgical division at Allergan, Inc. He recently served as a board Professorship and is the Ophthalmologist-in-Chief at New York Presbyterian member of WaveTec Vision Systems, Inc. and has a BS from Miami University and Hospital. In 2014, he was elected as President of the Columbia Doctors Faculty an MBA from Xavier University. Practice Organization and was appointed Vice Dean for Clinical Affairs. Dr. Cioffi has received support from the National Eye Institute and has received many VYZULTA and the V design are trademarks of Bausch & Lomb Incorporated or its affi liates. awards throughout his career. He continues to mentor clinical and post-doctoral ©2017 Bausch & Lomb Incorporated. All rights reserved. VYZ.0360.USA.17 fellows that are now at academic institutions and in practices around world.

2018 New Horizons Forum 13

CLIENT APPROVAL: INSERTION NOTES: IMAGES: PUB: NONE background_blue_ CLOSE DATE: NONE CMYK_8.75X11.25.psd (CMYK; 300 ppi; 100%), VYZULTA_Logo_KO.eps VERSION NONE ECD NONE NOTES: INSERTION DATE: NONE None (1333%, 96.45%), B+L_logo_CMYK.ai (17.65%), UNIT NONE GCD NONE IMAGES: VYZULTA_BottleAndBox_ background_blue_CMYK_8.75X11.25.psd BLEED 8.75” x 11.25” CSM NONE CMYK_Final.psd (CMYK; 539 (CMYK; 300 ppi; 100%), VYZULTA_Logo_ ppi; 55.62%) KO.eps (1333%, 96.45%), B+L_logo_CMYK. TRIM 8.5” x 11” AD NONE ai (17.65%), VYZULTA_BottleAndBox_ CMYK_Final.psd (CMYK; 539 ppi; 55.62%) LIVE 7.5” X 10” CW NONE

VIEWING 8.5” x 11” ACCT NONE FONTS: Interstate (Bold, Regular, GUTTER None PM NONE Light) SCALE 1” : 1” PROD. ART. MARK NICHOLSON DPI NONE PROOF NONE INKS: 8.5” X 11” NONE ACTUAL PROD. MGR. Cyan, Magenta, Yellow, Black BAU7014_GLAUCOMA_360_AD_8.5X11_M01.INDD DOCUMENT PRINTED AT: NONE 1-4-2018 2:48 PM NEED TO TURN DOWN IOP? FOR PATIENTS WITH OPEN-ANGLESPEAKERS, GLAUCOMA MODERATORS, OR OCULAR HYPERTENSION PARTICIPANTS1 TURN TO THE STRENGTH OF SIMBRINZA®1,2 SIMBRINZA® SUSPENSION HAS THE STRENGTH TO TURN DOWN IOP WHEN ADDED TO A PGA2 SIMBRINZA® Suspension should be taken at least fi ve (5) minutes apart from other topical ophthalmic treatments.1 JEFFREY L. CLELAND, PHD E. RANDY CRAVEN, MD, FACS President and Chief Executive Officer 2* Associate Professor UP TO 7.1 mm Hg ADDITIONALGraybug Vision, Inc. IOP REDUCTION FROM BASELINE Wilmer Eye Institute and Johns Hopkins University Dr. Cleland has 25 years of industry experience Medical DirectorPrimary End Point2 in research and development. He has played Treatment Arm 8 AM 10 AM 3 PM 5 PM Wilmer Eye• Institute Mean diurnal – Bethesda IOP (IOP major roles in obtaining more than $450 million Dr. Craven is anaveraged associate over professor all daily at thetime in capital including over $300 million in capital points) at week 6 between Baseline 24.5 22.9 21.7 21.6 Wilmer Eye Institute. He is an associate professor PGA + SIMBRINZA® raised as CEO of Versartis (VSAR), where he led treatment groups at Johns Hopkins University.7.1mm Hg In the 1990s until 2013, he was the president of Suspensionone of the top (n=83)biotech IPOs of all time. He has directly managed all aspects of 2 † Glaucoma Consultants reductionof Colorado in the DenverKey areaSecondary and participated End Points in well pharmaceutical development Wandeek late-stage 6 research.19.4 Dr. Cleland15.8 has authored17.2 15.6 over 100 clinical trials. He served as the chief• Meanof Glaucoma IOP for at each the Kingdaily Khaled time more than 100 articles and 4 books, and holds several issued patents. He holds Eye Specialist Hospital in Riyadh Saudi Arabiapoint from 2013at week to 2017. 6 His current a PhD in Chemical Engineering from the Massachusetts Institute of Technology. Baseline 24.3 22.6 21.3 role is 2the1.2 Medical Director of the Bethesda • location Mean diurnal for Wilmer change Eye Institute. from PGA + Vehicle (n=92) baseline to week 6 † † Di erences (mm Hg) at week 6 time Week 6 21.5 20.3 20.0 20.1 points between treatment groups were -2.1 (P=0.0002), -4.6 (P<0.0001), -2.8 (P<0.0001), and -4.4 (P<0.0001).2

ANNE L. COLEMAN, MD, PHD EMMETT CUNNINGHAM, JR., 5.7 mm Hg ADDITIONAL MEAN DIURNAL IOP REDUCTION FROMMD, BASELINE PHD, MPH2 * Vice Chair of Department of Ophthalmology Stein Eye Institute Managing Partner Frances and Ray Stark Foundation Professor Clarus Ventures * A prospective, randomized,of Ophthalmology multicenter, double-blind, parallel-group study of 182 patients with open-angle glaucoma and/or ocular Study Design: Dr. Cunningham is an internationally recognized hypertension receiving treatmentStein with Eye a InstitutePGA. PGA of thetreatment David Geffen consisted School of travoprost, latanoprost, or bimatoprost. Patients in the study were randomized to adjunctive treatmentof Medicine, with SIMBRINZA® University of Suspension California, Los (n=88) Angeles or vehicle (n=94). The primary eª cacyspecialist end inpoint infectious was the and di inflammatory erence in mean eye diurnal IOP (IOP averaged over Professorall daily time of Epidemiology points) at week 6 between treatment groups. Key secondary enddisease. points He included joined Clarus IOP atVentures week 6in for 2006. each daily time point (8 AM, 10 AM , 3 PM Jonathan, and 5 PM and) and Karin the Fielding di erence School in meanof Public diurnal IOP change from baseline to weekHe is Director6 between of the treatment Uveitis Service groups. at California2 Health, University of California, Los Angeles Pacific Medical Center, Adjunct Clinical Professor of Ophthalmology at Stanford INDICATIONS AND USAGE Corneal Endothelium—There is an increased potential for developing SAFETYDr. Coleman’s INFORMATION research includes (continued) the etiology, diagnosis, treatment, and societal EventsUniversity, occurring and ain Research approximately Associate 3 atto The 9% Francisof the I.subjects, Proctor Foundation, in descending UCSF SIMBRINZA® (brinzolamide/brimonidine tartrate ophthalmic suspension) corneal edema in patients with low endothelial cell counts. impact of glaucoma, cataracts, and age-related macular degeneration, including order,School included of Medicine. corneal Dr. staining/erosion, Cunningham received photophobia, his MD and MPH from erythema, Johns 1%/0.2% is a fi xed combination indicated in the reduction of elevated Adverse Reactions ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, Severe Hepatic or Renal Impairment (CrCl <30 mL/min)— SIMBRINZA®quality-of-life Suspensionresearch for patients impacted by these eye diseases. Dr. Coleman Hopkins University, his PhD from UC San Diego, and completed his residency intraocular pressure (IOP) in patients with open-angle glaucoma or SIMBRINZA® Suspension has not been specifi cally studied in these eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, In two clinical trials of 3 months’ duration with SIMBRINZA® Suspension, ocular hypertension. patients and is not recommended. studied chemistry at Duke University, received her MD degree with Alpha Omega gastrointestinaland fellowship symptoms, at UCSF. He asthenia,completed conjunctival additional fellowships blanching, at abnormalMoorfields Eye theAlpha most honors frequent from reactions the Medical associated College of withVirginia, its usecompleted occurring an ophthalmology in vision,Hospital and inmuscular London andpain. the Wilmer Eye Institute. Dosage and Administration Acute Angle-Closure Glaucoma—The management of patients with acute approximately 3 to 5% of patients in descending order of incidence The recommended dose is one drop of SIMBRINZA® Suspension angle-closure glaucoma requires therapeutic interventions in addition to included:residency blurred at University vision, of eye Illinois-Chicago irritation, dysgeusia followed by (bad a glaucoma taste), fellowshipdry mouth, at Drug Interactions in the a” ected eye(s) three times daily. Shake well before use. ocular hypotensive agents. SIMBRINZA® Suspension has not been studied andJohns eye Hopkinsallergy. University,Adverse reactionand earned rates a PhD with in epidemiologySIMBRINZA® from Suspension UCLA in 1997. Consider the following when prescribing SIMBRINZA® Suspension: SIMBRINZA® Suspension may be used concomitantly with other topical in patients with acute angle-closure glaucoma. were comparable to those of the individual components. Treatment Concomitant administration with oral carbonic anhydrase inhibitors is ophthalmic drug products to lower intraocular pressure. If more than Contact Lens Wear—The preservative in SIMBRINZA® Suspension, discontinuation, mainly due to adverseALAN reactions,S. CRANDALL, was reported MD in 11% not recommended due to the potentialEUGENE additive DE e”JUAN, ect. Use JR., with MD high- one topical ophthalmic drug is being used, the drugs should be benzalkonium chloride, may be absorbed by soft contact lenses. Contact of SIMBRINZA® Suspension patients. dose salicylate may result in acid-base and electrolyte alterations. Use administered at least fi ve (5) minutes apart. lenses should be removed during instillation of SIMBRINZA® Suspension Brinzolamide 1% Presidential Professor of Ophthalmology with CNS depressants may resultFounder in an additive and Vice-Chairman or potentiating e” ect. but may be reinserted 15 minutes after instillation. Use with antihypertensives/cardiac glycosides may result in additive In clinical studies of brinzolamideand ophthalmic Visual Services; suspension Senior Vice 1%, Chair,the most Director ForSight Labs IMPORTANT SAFETY INFORMATION or potentiating e” ect on lowering blood pressure. Use with tricyclic Severe Cardiovascular Disease—Brimonidine tartrate, a component of frequently reported adverse eventsof Glaucoma reported and in 5Cataract; to 10% ofCo-Director, patients were antidepressants may blunt the hypotensive e” ect of systemic clonidine SIMBRINZA® Suspension, had a less than 5% mean decrease in blood blurred vision and bitter, sour, or unusual taste. Adverse events occurring Dr. de Juan serves as Vice-Chairman of ForSight Contraindications Division of International Ophthalmology and it is unknown if use with this class of drugs interferes with IOP pressure 2 hours after dosing in clinical studies; caution should be in 1 to 5% of patients were blepharitis, dermatitis, dry eye, foreign body Labs and is the Jean Kelly Stock Distinguished SIMBRINZA® Suspension is contraindicated in patients who are John A. Moran Eye Center Global Outreach lowering. Use with monoamine oxidase inhibitors may result in exercised in treating patients with severe cardiovascular disease. sensation, headache, hyperemia, ocular discharge, ocular discomfort, hypersensitive to any component of this product and neonates and Division, University of Utah increased hypotension. Professor in Ophthalmology at UCSF. He has ocular keratitis, ocular pain, ocular pruritus, and rhinitis. infants under the age of 2 years. Potentiation of Vascular Insu€ ciency—Brimonidine tartrate, a component participated in the development of a number of SIMBRINZA® Suspension, may potentiate syndromes associated with Dr. Crandall is a member of the American For additional information on SIMBRINZA® Suspension, please refer to Warnings and Precautions vascular insu‰ ciency. It should be used with caution in patients with Brimonidine Tartrate 0.2% the Brief Summary of Prescribingof new Information technologies on and the venture-funded following page. In clinical studies of brimonidineAcademy tartrate of 0.2%, Ophthalmology, adverse events American Society Sulfonamide Hypersensitivity Reactions—Brinzolamide is a sulfonamide, depression, cerebral or coronary insu‰ ciency, Raynaud’s phenomenon, References: 1. SIMBRINZA® Suspension [prescribing information]. Fort Worth, TX: Alcon Laboratories Inc; occurring in approximately 10 to 30% of the subjects, in descending companies. He has previously served as Professor of Ophthalmology at USC and and although administered topically, it is absorbed systemically. orthostatic hypotension, or thromboangiitis obliterans. of Cataract and Refractive Surgery, American Glaucoma Society, the European 2015. 2. Fechtner RD, Myers JS, Hubatsch DA, Budenz DL, DuBiner HB. Ocular hypotensive e ect of order of incidence, included oral dryness, ocular hyperemia, burning fi xed-combinationCEO at the brinzolamide/brimonidineDoheny Institute, adjunctive Co-Director to a prostaglandin of Vitreoretinal analog: a randomized Service clinical at the Sulfonamide attributable adverse reactions may occur. Fatalities have Society of Cataract and Refractive Surgeons, as well as the International Intra- trial. Eye (Lond). 2016;30(10):1343-1350. Contamination of Topical Ophthalmic Products After Use—There have and stinging, headache, blurring, foreign body sensation, occurred due to severe reactions to sulfonamides. Sensitization may Wilmer Eye Institute at Johns Hopkins University School of Medicine, Director of been reports of bacterial keratitis associated with the use of multiple- fatigue/drowsiness,Ocular Implant Club. conjunctival He received follicles,his medical ocular degree allergic from thereactions, University of recur when a sulfonamide is readministered irrespective of the route of dose containers of topical ophthalmic products. These containers have andUtah ocular School pruritus. of Medicine. Dr. Crandall completed his internship in surgery at the the Microsurgery Advanced Design Laboratory, and Joseph E. Green Professor of administration. If signs of serious reactions or hypersensitivity occur, been inadvertently contaminated by patients who, in most cases, had a Ophthalmology.See He more completed e’ cacyhis MD and and informationinternship training at at the University of discontinue the use of this preparation. concurrent corneal disease or a disruption of the ocular epithelial surface. University of Pennsylvania Medical Center as well as his residency and fellowship www.TurnDownIOP.com in ophthalmology at the Scheie Eye Institute, University of Pennsylvania. He South Alabama College of Medicine. joined the University of Utah Ophthalmology Department in 1981. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 © 2017 Novartis 9/17 SMZ-1349618

2018 New Horizons Forum 15 SPEAKERS, MODERATORS, PARTICIPANTS

TEJAL DESAI, PHD ROBERT D. FECHTNER, MD Ernest L. Prien Endowed Professor and Chair, Professor Dept. of Bioengineering and Therapeutic Institute of Ophthalmology and Visual Science Sciences, School of Pharmacy and Medicine Director University of California, San Francisco Glaucoma Division, Rutgers New Jersey Medical School Dr. Desai is the founding director of the UCSF/ UC Berkeley Masters Program in Translational Dr. Fechtner chairs the Institutional Review Board Medicine. She is Chair-Elect of the American for human subject research at the New Jersey Institute for Medical and Biological Engineering College of Fellows. Dr. Desai’s Medical School in Newark. He is also the Executive Vice President of the World research includes materials engineering, cell biology, tissue engineering, and Glaucoma Association. Dr. Fechtner is a highly regarded glaucoma educator. pharmacological delivery systems to address issues concerning disease and He has organized major glaucoma symposia for the American Academy of clinical translation. She received her BS from Brown University in biomedical Ophthalmology, American Society of Cataract and Refractive Surgery, the World engineering and was awarded a PhD in bioengineering jointly from UCSF and Glaucoma Congress and the American Glaucoma Society. He has served on the UC Berkeley. In 2015, she was elected to the National Academy of Medicine. editorial boards of American Journal of Ophthalmology, Journal of Glaucoma, Review of Ophthalmology, and Video Journal of Ophthalmology.

JAG DOSANJH MORGAN V. FEDORCHAK, PHD Senior Vice President, Eye Care President and Chief Technology Officer Allergan, Inc. Otero Therapeutics, Assistant Professor of Ophthalmology, Jag is responsible for the commercialization Bioengineering, and Clinical and Translational of the entire Eye Care portfolio in the US and Science co-chairs the R&D Governance Board for the University of Pittsburgh pipeline development. Prior to this, he led the Dr. Fedorchak is the Director of the Ophthalmic Retina, , and SkinMedica business Biomaterials Laboratory at the University units, and the Managed Markets and Government Affairs. Jag also led the Global of Pittsburgh and a co-inventor of the SoliDrop technology, the basis for Strategic Marketing developing strategy and delivery of the pipeline within the Otero’s controlled release glaucoma eye drop technology. She received her pharmaceutical, device and aesthetics portfolios. Prior to joining Allergan, Jag BS in Chemical Engineering from Carnegie Mellon University and her PhD in worked at GlaxoSmithKline in several executive roles in both Europe and the US. Bioengineering from the University of Pittsburgh. He holds a BA in Business Studies from Sheffield in the UK.

MALVINA EYDELMAN, MD ANDREW GITKIN Division Director, Division of Ophthalmic Managing Director and Head of West Device Evaluation Coast Biotechnology Investment Banking FDA Piper Jaffray Dr. Eydelman is a board-certified ophthalmologist. Andrew has over 25 years of healthcare She received her undergraduate degree in investment experience, most recently at Moelis Electrical Engineering from Cooper Union for the & Company, where he was a Senior VP in the Advancement of Science and Art. She received life sciences investment banking group. Andrew her MD degree from Harvard Medical School and a PhD in Health Sciences and was previously with Saddle Point Asset Management where he was a managing Technology from Massachusetts Institute of Technology. In 1995, Dr. Eydelman member and healthcare portfolio manager. Prior to that, he was a VP at Tavistock joined the FDA and has played a key role in assuring the safety and effectiveness Life Sciences and was CEO of Zephyr Sciences. Andrew was also a senior of ophthalmic medical devices. She has been involved in standardization of healthcare analyst in equity research at UBS and SalomonSmithBarney where he ophthalmic devices as the US Expert Delegate to the International Standards was awarded rankings by Institutional Investor and Greenwich Associates. Organization and FDA’s Liaison to the American National Standards Institute’s Committee for Ophthalmic Devices.

2018 New Horizons Forum 17 SPEAKERS, MODERATORS, PARTICIPANTS

MICHAEL H. GOLDSTEIN, MD, MBA MARK S. HUMAYUN, MD, PHD RAY KRAUSS, MBA SHAN LIN, MD Chief Medical Officer Cornelius J. Pings Chair in Biomedical Sciences, Chief Executive Officer Professor, Clinical Ophthalmology, Director, Ocular Therapeutix Professor of Ophthalmology, Biomedical Camras Vision Glaucoma Service Engineering, and Integrative Anatomical UCSF and the Zuckerberg San Francisco Dr. Goldstein joined Ocular Therapeutix in 2017. Sciences, Director Ray has 35 years executive experience General Hospital Prior to that, Dr. Goldstein served as CMO of USC Institute for Biomedical Therapeutics in the medical device industry, including Dr. Lin’s interests include: angle closure glaucoma; Applied Genetic Technologies Corp, a clinical- Co-Director 10 years at Johnson & Johnson (venture stage biotechnology company focused on the USC Roski Eye Institute capital/ophthalmology). He joined Summit glaucoma among Asians; cyclodestructive procedures; and the role of cataract surgery in treatment of rare ophthalmic diseases. Before Dr. Humayun has dedicated 30 years to the Technology as COO, the first company to glaucoma treatment. His past honors include the Heed Fellowship Award, the joining AGTC, Dr. Goldstein served as CMO and VP of Clinical Research at Eleven development of the first FDA-approved bioelectronic artificial retina to restore sight receive FDA clearance for PRK in 1995. He has been CEO of several startups, American Glaucoma Society and The Glaucoma Foundation’s Clinician-Scientist Biotherapeutics. Dr. Goldstein serves as Co-Director, and External Disease to the blind and enable them to see large objects and letters. He has more than raised financing from Angel Investors and VC firms, and has led the sale Awards, and the Mid-Career Award by the AGS. As a Principal Investigator, Service and Assistant Professor of Ophthalmology at the New England Eye 200 peer-reviewed publications and 114 issued patents and is the recipient of the of two companies to strategic partners. Ray holds BS and MS degrees in his OHTS study was funded by the NIH, in addition to him receiving many Center and Tufts University School of Medicine. Dr. Goldstein holds an MD and 2015 National Medal of Technology and Innovation — the nation’s highest award Electrical Engineering and an MBA. industry-funded trials including the Memantine Glaucoma Trial by Allergan and an MBA from Northwestern University. for technological achievement. the Ranibizumab-Adjunctive Study for Ahmed Valve Surgery by Genentech. He has received the AAO’s Achievement Award, Secretariat Award, and Senior Achievement Award.

HENRY HSU, MD MALIK Y. KAHOOK, MD RICHARD A. LEWIS, MD WILLIAM J. LINK, PHD Chief Executive Officer Slater Family Endowed Chair of Ophthalmology, Co-founder Founder, Flying L Partners Allysta Pharmaceuticals Vice Chair of Clinical and Translational Research, Sacramento Eye Consultants Managing Director, Versant Ventures Chief, Glaucoma Service and Director of Dr. Hsu has extensive experience in all phases Glaucoma Fellowship, Professor of In addition to his clinical practice, Dr. Lewis is In 1987 Bill founded and served as chairman of drug development in multiple indications, Ophthalmology involved in clinical research trials in anterior and CEO of Chiron Vision (sold to Bausch + including glaucoma, dry eye, and retinal diseases. University of Colorado Aschutz Medical segment disease and glaucoma . He Lomb). He founded and served as President Prior to founding Allysta, Henry was CEO of Campus previously served as President of both the of American Medical Optics, which was sold Altheos. He has led clinical development teams Dr. Kahook is Professor of Ophthalmology American Society of Cataract and Refractive to Allergan. Bill served on the Board of AMO’s at Molecular Partners, CoMentis, and Plexxikon. Allysta is partnered with D. and The Slater Family Endowed Chair in Ophthalmology at the University of Surgery and the American Glaucoma Society. Dr. Lewis is the medical Editor successor company, Advanced Medical Optic, later acquired by Abbott and Western Therapeutics Institute (Japan) to advance a novel multi-kinase inhibitor Colorado School of Medicine. He is Vice Chair of Clinical and Translational Emeritus of Glaucoma Today and on the editorial board of the Journal of Cataract later acquired by Johnson & Johnson. Bill serves on the Board of several private (H1337) for glaucoma into clinical trials in early 2018 in the United States. Research and is Chief of the glaucoma service and Director of the glaucoma and Refractive Surgery, Journal of Glaucoma, and Ocular Surgery News. Dr. Lewis companies and three public companies: Glaukos, Second Sight and Edwards Dr. Hsu obtained his MD from UCSF. fellowship at the University of Colorado Eye Center. Dr. Kahook has also received attended UC Berkeley and received his MD from Northwestern University Medical Lifesciences. Previously, Bill was Assistant Professor, at Indiana University School numerous awards and filed for over 30 patents with 20 licensed by companies School. His completed his residency at the UC Davis, and a fellowship at the of Medicine. He received his BS, MS and PhD in Mechanical Engineering from for development. Four of his devices are currently in human trials or available University of Iowa. Purdue University. globally for clinical use.

ANDREW D. HUBERMAN, PHD ROBERT KISSLING, MD MELISSA LIEW, MD CYNTHIA MATTOX, MD, FACS Assistant Professor, Neurobiology and Vice President, Medical Affairs Vice President and US Medical Unit Head, Associate Professor and Vice-Chair, Ophthalmology Bausch + Lomb Ophthalmology Department of Ophthalmology at Tufts Stanford University School of Medicine Novartis Alcon Pharmaceuticals University School of Medicine; Robert Kissling, MD has more than 15 years Director of the Glaucoma and Cataract Dr. Huberman received his PhD in Neuroscience of experience in the eye care industry and Dr. Liew is responsible for medical affairs Service at the New England Eye Center from UC Davis. From 2005-2010 he was a including Pharmacia, strategy across the ophthalmology portfolio. Dr. Mattox has served on the American Helen Hay Whitney Postdoctoral Fellow at Novartis, QLT, Galderma, and Bausch + Lomb. Previously, Melissa was VP and Therapeutic Stanford University. From 2011 to 2015, he Area Head for Retina at Novartis, leading Glaucoma Society (AGS) Board since 2008 and was an Assistant Professor in the Departments of Neuroscience, Biology and retina clinical development strategy and global development programs. Prior was elected President in 2017. She has served on the Health Policy committee Ophthalmology at UC San Diego. In 2016, joined the faculty at Stanford to Novartis, she worked at Pfizer Ophthalmics on translational to late stage of the American Academy of Ophthalmology (AAO) for many years. In 2014, she University. Dr. Huberman is a McKnight Foundation Neuroscience Scholar, a development including retina, glaucoma and dry eye projects. As a Wellcome received the Outstanding Advocate Award from the AAO, and in 2016 was elected Biomedical Scholar of the Pew Charitable Trust and in 2017, he received the Trust researcher, her genetic epidemiology of retinal diseases and macular to a four-year term on the AAO Board of Directors. Along with her busy practice, ARVO Cogan Award for Contributions to Vision Science and Ophthalmology. Dr. pigment research earned her a European Society of Ophthalmology award. Dr. Mattox trains glaucoma fellows and residents in glaucoma and cataract Huberman is member of the Glaucoma Research Foundation Catalyst for a Cure Melissa received her MD from University College, London and completed her management and surgery, and has received the Resident Teaching Award three Biomarker Initiative. Ophthalmology residency at Moorfields and a glaucoma fellowship at Wills Eye. times. She is a board certified Ophthalmologist.

18 Glaucoma Research Foundation 2018 New Horizons Forum 19 SPEAKERS, MODERATORS, PARTICIPANTS

Working together. FELIPE MEDEIROS, MD, PHD CHRISTOPHER A. MULLER Professor of Ophthalmology Chief Commercial Officer Vice Chair of Technology Mati Therapeutics, Inc. Duke University School of Medicine Prior to Mati Therapeutics, Mr. Muller served as Naturally. Dr. Medeiros completed his MD and residency at the Chief Commercial Officer at QLT Inc. Before the University of Sao Paulo School of Medicine, that, he was responsible for several business units followed by a fellowship at the Hamilton at Abbott Medical Optics as VP, Eye Care, Medical Glaucoma Center at UC San Diego and PhD Marketing and the Refractive Business Unit with in Vision Science from the University of Sao Paulo. His research focuses on responsibility for VISX® and iFS laser platforms, contact lens solutions, artificial the development of innovative methods to diagnose and detect glaucoma. tear development and commercialization, plus ophthalmic surgical products. For Dr. Medeiros evaluates the impact of eye diseases on daily activities, using 15 years Mr. Muller was employed at Allergan Inc. where he built an extensive innovative techniques such as virtual reality. His laboratory was the first to use background across all ocular pharmaceutical and surgical products and Botox®, virtual reality to predict a clinically relevant functional outcome in medicine. including sales, health economics, worldwide medical marketing, and product management.

EYDIE MILLER-ELLIS, MD RAM PALANKI, PHARMD Professor of Clinical Ophthalmology Senior Vice President of Commercial, Director, Glaucoma Services Americas Scheie Eye Institute Santen Inc. While maintaining a busy glaucoma practice, Dr. Palanki brings over 15 years of Dr. Miller-Ellis lectures nationally and ophthalmology experience across marketing, internationally on glaucoma diagnosis and sales, reimbursement, commercial operations, www.ellex.com/SLT-ABIC-natural-partnership management. She is a three-time recipient of business development, and medical affairs. the Surgical Teaching Award at the Scheie Eye Institute, Co-Vice Chair of the Previously, he was Global Head of Marketing and Sales at Thrombogenics, Inc., A restorative approach to IOP control. American Academy of Ophthalmology’s (AAO) Ophthalmic Knowledge Base panel where he led the commercial launch for Jetrea®, a therapy for symptomatic for glaucoma, chair of the AAO’s COMPASS panel for glaucoma, and a 2008 VMA. Prior to that, Dr. Palanki served as Director of Global Marketing and ™ SLT and ABiC work to control IOP by a process of restoration of the natural outflow recipient of the AAO Achievement Award. She received her MD from the University Sales at NeoVista, Inc., and earlier, he held several positions at Genentech pathways. This is in contrast to traditional glaucoma and other MIGS procedures, of Pittsburgh and did her ophthalmology residency at UNC, Chapel Hill, and a as part of the team that developed and launched Lucentis®. Other past which attempt to mechanically change or bypass the pathway of aqueous outflow. glaucoma fellowship at Yale. positions include Eyetech Pharmaceuticals and Novartis Pharmaceuticals. Dr. Palanki earned his PharmD at Albany College of Pharmacy and completed his SLT stimulates a process of cellular regeneration to create a postdoctoral fellowship at Rutgers University in New Jersey. healthier, more porous TM structure. On average, SLT achieves THOMAS A. MITRO LEONARD PINCHUK, PHD a 30% reduction in IOP when used as a first-line therapy. President and Chief Operating Officer Chief Science Officer ABiC™ is a new ab-interno MIGS procedure that flushes out the Aerie Pharmaceuticals Inn Focus, Inc., a Santen company natural outflow channels, without damaging tissue, to achieve an Prior to serving as President and COO of Aerie Dr. Pinchuk co-founded Innovia LLC, which average IOP reduction of 30%*. Pharmaceuticals, Tom served as VP, Sales incubated and spun off into eight companies. and Marketing at Omeros Corp and ISTA In 2016 Santen Corporation acquired his Pharmaceuticals. He held various positions current company, InnFocus, Inc. His major ™ PREVIEW THE BREAKTHROUGH Tango Reflex at Allergan, Inc., including VP, Skin Care; VP, accomplishments include the invention or SLT/LFR/YAG LASER AT GLAUCOMA 360 Business Development; and VP, e-Business. Tom has been an invited guest co-invention of the modern-day angioplasty balloon and other cardiovascular speaker to the Ophthalmic Innovation Summit, Generic Drug industry, the stents, several biomaterials, a novel glaucoma shunt, and next generation LEARN MORE AT WWW.ELLEX.COM/SLT-ABIC-NATURAL-PARTNERSHIP Dermatology Leadership Council and OCTANe. He currently serves on the Board material. He received a BSc in Chemistry and an honorary of Directors at OCTANe. Tom received his BS degree from Miami University. Doctor of Science degree from McGill University and a PhD interdisciplinary

*E&OE. © 2018 Ellex Medical. * 228-eye ABiC 12-Month Case Series Data, presented at ASCRS 2016. Data on file. Ellex Medical. in Engineering and Chemistry from the University of Miami where he is a Research Professor of Biomedical Engineering. He was inducted into AIMBE and the National Academy of Engineering.

2018 New Horizons Forum 21 ELLEX-ABiC SLT-Glaucoma 360-2018.indd 1 19/12/2017 3:24 pm SPEAKERS, MODERATORS, PARTICIPANTS APRIL 12, 2018 WASHINGTON, DC RENAISSANCE WASHINGTON, DC DOWNTOWN HEATHER PRESTON, MD ANGELO RAGO 999 Ninth Street NW Washington Partner and Managing Director Head of Ophthalmic Diagnostics District Of Columbia 20001 TPG Biotech Carl Zeiss Meditec, Inc. Prior to TPG Biotech, Dr. Preston focused on Currently Mr. Rago is focused on Retina medical device and biotechnology venture and Glaucoma and the Routine Diagnostics capital investing at JP Morgan Partners. businesses. He joined ZEISS as Head of Business Previously, she was an Entrepreneur-in- Sectors and Innovation within the Strategic Residence with New Enterprise Associates. She Business Unit Ophthalmic Systems. Previously, worked at McKinsey & Co. where she was a leader of their pharmaceutical Mr. Rago held various management positions in Equipment Operations and and medical products consulting practice. Dr. Preston currently serves on the Global Customer Care for Abbott Medical Optics (AMO). Prior to AMO, he board of directors of Albireo, Inc., Alder BioPharmaceuticals, Otonomy, Inc., spent 17 years with Siemens Medical Solutions, where he held senior positions Unchained, Labs, Avalyn Pharmaceuticals, Azura Ophthalmics and Entasis, in both Service and Product Development areas. He holds a BS in Mechanical Inc. She earned her MD from the University of Oxford and completed a Engineering and an Executive Certification in Innovation & Strategy from MIT’s molecular biology post-doctoral fellowship at Dana Farber Cancer Institute, Sloan School of Business. Harvard University. She trained in at Massachusetts General Hospital and subspecialized in and at UCSF.

CHRIS PULLING MICHAEL R. ROBINSON, MD Chief Executive Officer Vice-President, Therapeutic Area Head, MicroOptx Anterior Segment and Consumer Eye Care Allergan, Inc. Prior to MicroOptx, Chris was CEO of The Integra Group, a contract research organization Dr. Robinson is a board-certified ophthalmologist CELEBRATING he founded in 2002. He led Integra from who completed 3 years of post-doctoral formation through acquisition by the world’s fellowship training at the National Eye Institute largest medical device CRO. At Integra, Chris with a focus on ocular drug delivery. Given his 10 YEARS and his staff supported over 400 medical device companies, and he was broad clinical and research background, Dr. Robinson has served in multiple integrally involved in over 30 PMA approvals and 10 FDA advisory panels. leadership roles at Allergan including Global Project Team Lead and Clinical OF INNOVATION Previous management experience also includes Medtronic. Chris has an MS in Lead on projects related to ocular drug delivery in dry eye, retina and glaucoma Biostatistics from the University of Minnesota and a BA in Mathematics from therapeutic areas. He has over 20 issued patents that include Bimatoprost SR Hamline University. and Brimonidine DDS, both in late stages of clinical development.

JANE RADY CHERYL ROWE-RENDLEMAN, PHD Vice President, Business Development Managing Consultant Johnson & Johnson Vision Omar Consulting Group, LLC UNITING OVER Prior to joining Johnson & Johnson Vision and Dr. Rowe-Rendleman is a clinical research and Abbott Medical Optics, Ms. Rady was a director development professional at Omar Consulting and the CEO of Integrated Genomics, Inc., held Group, an ophthalmology consulting practice 500 LEADERS senior positions within G.D. Searle & Co., and specializing in creating business, regulatory, headed venture investing in Monsanto focusing and clinical development know-how for people IN THE DEVELOPMENT OF on emerging technologies and businesses in biotechnology.Ms. Rady began and companies interested in eye diseases. A graduate of Princeton University GROUND-BREAKING her career with Abbott Laboratories. She received her Bachelor and Master of with graduate fellowships in developmental and degenerative ophthalmic Science from the University of Illinois in molecular biology/microbiology and her diseases from the University of Texas and UCSF Medical Schools, Cheryl has OPHTHALMIC TECHNOLOGIES MBA from Northwestern’s Kellogg School of Management. participated in over 100 US and Ex-US clinical development programs in areas of macular degeneration, diabetic retinopathy, ocular inflammation, anti-infectives, refractive disorders, glaucoma, and ocular surface disease.

WWW.OIS.NET /OIS.NET  @OISTWEETS  /OPHTALMOLOGYSUMMIT

2018 New Horizons Forum 23 SPEAKERS, MODERATORS, PARTICIPANTS

JOEL S. SCHUMAN, MD, FACS CLARK E. TEDFORD, PHD Professor and Chairman of Ophthalmology Co-Founder, President and Chief Executive NYU Langone Medical Center, New York Officer University School of Medicine LumiThera Professor of Electrical and Computer Engineering Dr. Tedford is one of the founders of LumiThera PRACTICAL REVIEWS from LEADING EXPERTS NYU Tandon School of Engineering and has served as President and CEO since the formation of the company. Previously he was VP Dr. Schuman was appointed Chair of the PEER-REVIEWED | OPEN-ACCESS | CONCISE and Chief Science Officer at PhotoThera. Prior to Department of Ophthalmology for the NYU that Dr. Tedford was the VP, Pharmaceutical Research at Omeros, and previously to ARTICLES | VIDEOS | NEWS Langone Medical Center in 2016. Dr. Schuman and his colleagues invented optical Omeros, Dr. Tedford was President of Solentix, Inc. During Dr. Tedford’s 25 years in coherence tomography (OCT), now standard of care for clinical use worldwide the pharmaceutical and medical device industry, he has held several scientific and for the diagnosis and management of . His team was also the first to executive management positions. Dr. Tedford received his PhD in pharmacology identify a molecular marker for human glaucoma, published in Nature Medicine in from the University of Iowa and completed post-doctoral work at the Loyola 2001. Dr. Schuman is a productive researcher, and has been continuously funded University Medical School. by the National Eye Institute since 1995. He serves on the Glaucoma Research Foundation’s Catalyst for a Cure Biomarker Initiative’s Advisory Board.

CHRISTIE SHAFFER, PHD KAREN Y. TORREJON, PHD Partner Founder, Chief Science Officer Hatteras Ventures Glauconix Therapeutics Christy Shaffer, PhD has over 25 years of During graduate research supported by the experience in the life science industry. Following National Science Foundation Graduate Research her career as a clinical scientist, international Fellowship Program (NSF GRFP), Dr. Torrejon project leader and Associate Director of invented 3D human eye tissue, known as the Pulmonary and Critical Care Medicine at 3D-human trabecular meshwork (3D-HTM). Burroughs Wellcome Co., she joined Inspire Pharmaceuticals. Dr. Shaffer serves She developed this proprietary technology which is currently being utilized for as a board member of five Hatteras portfolio companies and chairs three of Glauconix services. Dr. Torrejon has been recognized by the MIT technology them: Clearside (Chair), KinoDyn (Chair), and GrayBug (Executive Chair). She is a review and one of the “35 under 35” innovators of the year (2015). She receptor pharmacologist by training, earning her PhD in Pharmacology from the received her BS in both Chemistry and Physics from the State University of University of Tennessee Health Science Center. She received her post-doctoral New York (SUNY) at Albany and her PhD in Nanoscale Engineering from SUNY training at The Chicago Medical School and the University of North Carolina at Polytechnic Institute. Chapel Hill.

KULDEV SINGH, MD, MPH BRETT A. TRAUTHEN Professor of Ophthalmology Chief Scientific Officer Director of Glaucoma Service Ivantis, Inc. Stanford University School of Medicine Mr. Trauthen is the Chief Scientific Officer VIEW – DOWNLOAD – SUBSCRIBE Singh has served as President of the American for Ivantis, Inc, developer of the Hydrus Glaucoma Society and Executive Vice President Microstent, a novel surgical device for IOP FREE of the World Glaucoma Association. He is reduction in glaucoma. Prior to Ivantis, he was presently a Standing Member on the Medical the Chief Scientific Officer at Devax Inc and Devices Advisory Committee of the US Food and Drug Administration. Dr. Singh Conor Medsystems, developers of drug eluting coronary stents. Mr. Trauthen touchOPHTHALMOLOGY.com received his MD and MPH degrees from the Johns Hopkins University School of has directed over 20 clinical studies on novel technologies in ophthalmic and Medicine and was an Eleanor Naylor Dana Charitable Trust Fellow at the Wilmer cardiovascular disease. He has a BS in Engineering from UC Berkeley and an Eye Institute. He completed his ophthalmology residency at Casey Eye Institute MS is Engineering from UC Irvine. Touch Medical Media is the trading name of Touch Digital Media Ltd and his glaucoma fellowship at at the Bascom Palmer Eye Institute.

2018 New Horizons Forum 25 touchOPHTH A5 WGA2017 proof3.indd 1 04/01/2018 10:08 SPEAKERS, MODERATORS, PARTICIPANTS ACKNOWLEDGEMENTS

JAMES C. TSAI, MD, MBA MOLLY WALSH, MD President of New York Eye and Ear Infirmary Co-founder and Chief Executive Officer of Mount Sinai Retroject, Inc. BOARD OF DIRECTORS Chair of Ophthalmology, Mount Sinai Health System Dr. Walsh is the co-founder and CEO of Retroject, Delafield-Rodgers Professor of Ophthalmology, Inc, a company that she started with her late Board Chair DIRECTORS FOUNDERS Icahn School of Medicine at Mount Sinai colleague, Dr. David Epstein. Dr. Walsh is a Andrew G. Iwach, MD Dr. Tsai serves as Chair of the Glaucoma glaucoma specialist at Duke University Eye University of California Frederick H. Brinkmann John Hetherington, Jr., MD San Francisco, CA University of California Subcommittee of the National Eye Health Center where numerous patients are treated (Retired) Palo Alto, CA San Francisco, CA Education Program Planning Committee of the National Institutes of Health (NIH), daily for unnecessary vision loss due to the inadequacies of topical therapies. Her MEDIA AND research interests are focused on a device that enables delivery of therapeutic President and CEO Associate Examiner for the American Board of Ophthalmology, and Treasurer of the Thomas M. Brunner Timothy J. Dwyer H. Dunbar Hoskins, Jr., MD International Joint Commission on Allied Health Personnel in Ophthalmology. Dr. agents directly to the sites responsible for causing elevated intraocular pressure in STRATEGIC glaucoma, the trabecular meshwork and Schlemm’s canal. Glaucoma Research Foundation Private Investor American Academy of Tsai earned his MD from Stanford University School of Medicine and his MBA from San Francisco, CA Woodside, CA Ophthalmology (Retired) PARTNERS Vanderbilt University. He completed his residency at the Doheny Eye Institute and San Francisco, CA received his glaucoma fellowship training at the Bascom Palmer Eye Institute and Treasurer John G. Flanagan, PhD, FCOptom at Moorfields Eye Hospital and the Institute of Ophthalmology in London. Charles Wilmoth University of California, Berkeley Robert N. Shaffer, MD, FACS Sincere Thanks to our Wells Fargo Advisors, LLC. Berkeley, CA (1912 – 2007) Media and Strategic San Francisco, CA Partners TRACY M. VALORIE, MBA JEFF WELLS, PHARMD Adrienne L. Graves, PhD Senior Vice President and General Manager Senior Vice President of Clinical, Regulatory, Vice Chair Independent Director 4-R Vision US Pharmaceutical and Surgical and Quality Ruth D. Williams, MD San Francisco, CA Bausch + Lomb Glaukos Corporation Wheaton Eye Clinic Bryn Mawr Wheaton, IL Linda C. Linck Communications Ms. Valorie is the Senior Vice President Prior to working at Glaukos, Jeff was Senior VP Delta Gamma Foundation and General Manager of Bausch + Lomb of Product Development at Bioform, and held Secretary Lafayette, CA Healthegy Pharmaceuticals and Valeant Women’s Health and various roles at Santen Inc. including VP US R&D, Rick Halprin, CPA previously served as the Global Head of Glaucoma. VP Clinical and Regulatory Affairs for the US and Alcon Laboratories, Inc. (Retired) Dennis E. Singleton Jacqueline Jones Design Prior to that, Ms. Valorie was Pfizer’s Commercial Lead of Ophthalmology where Europe, and Director of Marketing. Prior to Santen, he worked at Bausch + Lomb, Fort Worth, TX Spieker Partners she was responsible for marketed products, mid-stage development portfolio, where he launched Lotemax and several other products. Jeff holds a BS and BA Menlo Park, CA Market Scope and long-range planning. Her 20+ year career has included roles in discovery from Northern University, a Masters in Management (MBA) from the Kellogg science, clinical development, early commercial assessment, marketing, and School at Northwestern University, and a PharmD from the University of . Robert L. Stamper, MD Ophthalmology Innovation strategic planning. Ms. Valorie has held board membership seats at The Glaucoma University of California Summit Foundation, ARVO foundation for Eye Research, and OWL. San Francisco, CA Ophthalmology Times Monica L. Vetter, PhD University of Utah Rotary Club of San Salt Lake City, UT STEVEN D. VOLD, MD Francisco Founder and Chief Executive Officer Martin B. Wax, MD touchOphthalmology Vold Vision PanOptica, Inc. Chief Medical Editor Bernardsville, NJ Glaucoma Today Dr. Vold founded Vold Vision after previously Mona Zander serving as Vice Chairman of the Department Mona and Ed Zander Family of Ophthalmology and Director, Division of Foundation Carmel, CA Glaucoma at the Scott and White Eye Institute and Texas A&M College of Medicine in Temple, Texas. He has been listed in the Consumer’s Research Council of America’s Guide to America’s Top Ophthalmologists every year since 2002. He currently serves as Chief Medical Editor of Glaucoma Today, and co- founded the American-European Congress of Ophthalmic Surgery. Dr. Vold also co-founded the ophthalmic device company Ocunetics, Inc. whose intellectual property was exclusively licensed by IRIDEX Corporation in 2011.

2018 New Horizons Forum 27 GLAUCOMA RESEARCH FOUNDATION

Our Proud Legacy… Founded in 1978 in San Francisco, Glaucoma Research Foundation was created to encourage innovative research to find better ways to care for people with glaucoma and ultimately find a cure.

Over the past 40 years, Glaucoma Research Foundation has funded pioneering and transformational studies to advance the field of glaucoma. An important funding priority is fostering collaborative research in order to speed the pace of discovery. Landmark projects include the Collaborative Normal Tension Glaucoma Study, the first controlled clinical trial to establish that lowering eye pressure preserves vision, and the establishment of the Catalyst for a Cure (CFC) GRF founders in 1989 (from left to right): the late Robert Shaffer, MD, H. Dunbar Hoskins, Jr., MD, and John Hetherington, Jr., MD research consortium. SAVE THE DATE! Established in 2001, our first CFC team focused on neuroprotection and fundamentally changed how the scientific and medical communities view vision loss in glaucoma. Based on this successful model, the second CFC team was recruited and charged with identifying new biomarkers to indicate the earliest signs of glaucoma. The researchers have moved their investigations from the laboratory into the clinic for human studies of the most promising biomarkers they have identified. The impact of this research will be valuable for both patients and doctors as it has the potential to transform how glaucoma is diagnosed and managed in the future. 2019 …and Inspired Future New Horizons Forum COMMITMENT TO EDUCATION AND AWARENESS Glaucoma Research Foundation remains a principal source of information and support for doctors, patients and their families. We distribute more than 120,000 issues of our Gleams newsletter three times a year through the mail, by doctors’ offices and by email. Our website, www.glaucoma.org, helps more than 4 million visitors annually with useful and accurate information. Both our website and our educational booklet “Understanding and Living with Glaucoma” continue to be primary resources for patients seeking to learn more about their glaucoma diagnosis, treatment options, Friday, February 8, 2019 and Glaucoma Research Foundation’s research initiatives. Palace Hotel, San Francisco

THE CURE IS IN SIGHT CAMPAIGN In April 2017, The Cure is in Sight — The Campaign for Glaucoma Research Foundation was launched with the goal to raise $15 million by June 2018. This historic fundraising endeavor will reinforce our mission, strengthen our education and support efforts, and make possible great strides in scientific discovery. In 2018, we will close the Campaign and mark the 40th anniversary of the founding of Glaucoma Research Foundation. As we celebrate these important milestones, we incredibly grateful for the outstanding support and dedication of our donors and volunteers. Please direct early inquiries to [email protected] Because of you, the cure is truly in sight. www.glaucoma360.org

28 Glaucoma Research Foundation